Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 7/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.32 |
| ▸ | PARP1 | P09874 | 5/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6368262 | 0.89 | CXCR2 (0.38) | PARP1CXCR2 | |
| SCHEMBL6367367 | 0.84 | CXCR2 (0.32) | PRMT5WDR77CXCR2 | |
| SCHEMBL6367286 | 0.82 | LMNA (0.40) | PARP1CXCR2 | |
| SCHEMBL6366723 | 0.81 | AR (0.39) | RIPK1CXCR2 | |
| SCHEMBL6371104 | 0.80 | MEN1 (0.40) | PARP1RIPK1 | |
| SCHEMBL6371852 | 0.79 | PDE2A (0.39) | ALPL | |
| SCHEMBL17604167 | 0.77 | PRMT5 (0.36) | CHEK1PRMT5WDR77PARP1 | |
| Hydrochloric Acid SCHEMBL17604355 | 0.76 | PRMT5 (0.35) | CHEK1PRMT5WDR77PARP1 | |
| SCHEMBL6366943 | 0.76 | ADORA2A (0.38) | — | |
| SCHEMBL6365807 | 0.76 | PDE9A (0.39) | TNKSTNKS2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | CHEK1 2976/4885PRMT5 1738/4885WDR77 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.